TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05168852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formlabs Permanent CB Resin
Description: Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formlabs Permanent CB Resin
Description: Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
Study: NCT05970978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regular treatment
Description: IBI112 200mg s.c. at week 0, 12, 24 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Description: IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
Study: NCT05912036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT
Description: CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
Study: NCT05595603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4mg ZOL loaded gentamicin PMMA
Description: During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin PMMA
Description: During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
Study: NCT06140628

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®
Description: Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®
Description: Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
Study: NCT04381624

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise program
Description: exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
Study: NCT05031117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Epidural Technique
Description: Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25G Dural Puncture Epidural Technique
Description: 25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
Study: NCT05320354

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbial ID test
Description: In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
Study: NCT06659146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superficial hyperthermia
Description: Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superficial hyperthermia
Description: Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superficial hyperthermia
Description: Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
Study: NCT06658977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Description: One Triumeq tablet per day
Study: NCT06660758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feeding tube (Entarik)
Description: Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
Study: NCT06197152

Intervention type: OTHER
Intervention: Nasopharyngeal swabs and biological collection
Description: * Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection

Intervention type: OTHER
Intervention: Nasopharyngeal swabs and biological collection
Description: * Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection
Study: NCT06658171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training and stimulus control
Description: Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: 1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping.
Study: NCT06619392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 Placebo
Description: HRS-2129 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 Placebo
Description: HRS-2129 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 Placebo
Description: HRS-2129 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 Placebo
Description: HRS-2129 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129 Placebo
Description: HRS-2129 Placebo
Study: NCT01312025

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified laparoscopic cholecystectomy
Study: NCT05920811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional obturator
Description: restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 d printed obturator
Description: restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
Study: NCT04362800

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MRI at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro-Encephalography-High Density
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-Encephalography-High Density
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
Study: NCT06149221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTAP
Description: Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
Study: NCT04858503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based cardiac rehabilitation enhancement intervention
Description: Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
Study: NCT05777850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cavotricuspid isthmus ablation
Description: Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-power short-duration ablation
Description: Point-by-point 90W applications at the CTI ablation during 4 seconds.
Study: NCT04826991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active UV Device
Description: Active water treatment system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive UV Device
Description: Inactive water treatment system
Study: NCT06268483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia
Description: Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia
Description: Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry, D-mannose, propolis extract, tumeric and Boswellia
Description: Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry, D-mannose, propolis extract, tumeric and Boswellia
Description: Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
Study: NCT04436783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Epley Maneuver System (VREMS)
Description: The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional Handout (IH)
Description: Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
Study: NCT06370949

Intervention type: DRUG
Intervention: Bupivacain
Description: Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain

Intervention type: DRUG
Intervention: bupivacain+dexmedetomidine
Description: Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
Study: NCT05300646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal mindfulness-based stress reduction
Description: An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
Study: NCT04945473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic placement of additional sutures
Description: A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
Study: NCT06293534

Intervention type: DIAGNOSTIC_TEST
Intervention: TSH,T3,T4
Description: Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
Study: NCT05007197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Effect of Diabetes Education Based on Learning Modality
Description: After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet.
Study: NCT05580770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Mirdametinib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Mirdametinib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Mirdametinib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Mirdametinib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: BGB-3245 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: BGB-3245 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: BGB-3245 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: BGB-3245 administered orally
Study: NCT05497739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Description: 5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic chemotherapy
Description: Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
Study: NCT05679661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunonutrition
Description: Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunonutrition
Description: Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral chlorhexidine decontamination
Description: Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral chlorhexidine decontamination
Description: Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
Study: NCT04716686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
Study: NCT06513741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Workshop
Description: Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times
Study: NCT06631469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised behavioural sustainable and healthy dietary recommendations
Description: Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalised sustainable and healthy dietary recommendations
Description: Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
Study: NCT05382884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartumcare.ca (Web-Enabled Intervention)
Description: Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
Study: NCT05545787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection
Description: During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot snare endoscopic mucosal resection
Description: During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
Study: NCT04830306

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Completion of exercise in accordance with assigned protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Completion of exercise in accordance with assigned protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Completion of exercise in accordance with assigned protocol
Study: NCT04107636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum assisted biopsy
Description: First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional lumpectomy
Description: After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.